Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin in Chronic Kidney Disease
NCT03223883Phase 2Completed
- Start
- Jun 2018
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) and No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity (2 arms). Primary endpoint: Brachial Artery-Flow Mediated Dilation at 12 months. Started Jun 2018; status: completed.
02
Conditions
chronic kidney disease (CKD)No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on NCT03223883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03223883.